source
- Fulcrum Therapeutics abandons its only sickle cell drug after FDA cites concerns linked to withdrawn cancer therapyFulcrum Therapeutics announced it is ending development of its sole clinical‑stage sickle cell medicine. The move follows feedback from the U.S. Food and Drug Administration that referenced a rece…
- Obesity care startup Ilant Health secures $15M Series A fundingIlant Health, a startup focused on obesity care, announced a $15 million Series A financing round. The capital will be used to broaden its personalized treatment platform, which leverages virtual…